Drug points: Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment

BMJ

Volumn 314, Issue 7094, 1997, Pages 1593-

  Ramachandran, S ^a   Giles, P D ^a   Hartland, A ^b  

^a MANOR HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CIPROFIBRATE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; HEEL; HUMAN; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; CLOFIBRIC ACID; DRUG INTERACTIONS; HUMANS; HYPERLIPIDEMIAS; IBUPROFEN; KIDNEY FAILURE, ACUTE; MALE; RHABDOMYOLYSIS;

EID: 0030991199     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.314.7094.1593a     Document Type: Article

References (2)

1. Davison C, Benziger D, Fritz A, Edelson J. Absorption and disposition of 2-[4-(2,2-dichlorocyclopropyl)-phenoxy]-2-methyl-propanoic acid. WIN 35,833 in rats, monkeys and men. Drug Metab Dispos 1975; 3: 520–524.
2. Mills RFN, Adams SS, Cliffe EE, Dickinson W, Nicholson JS. The metabolism of ibuprofen. Xenobiotica 1973; 3: 589–598.